Division of Obstetrics and Gynecology, San Paolo Hospital Medical School, ASST Santi Paolo E Carlo, Via Antonio di Rudinì 8, 20142, Milan, Italy.
Division of Obstetrics and Gynecology, San Gerardo University Hospital, Monza, Italy.
Reprod Sci. 2022 Jun;29(6):1710-1720. doi: 10.1007/s43032-021-00745-6. Epub 2021 Oct 1.
Pelvic floor disorders (PFDs) include a series of conditions that can be poorly tolerated, negatively affecting the quality of life. Current treatment options show unsatisfactory results and new ones are therefore needed. Stem cell (SC) therapy might be an alternative treatment strategy. This systematic review aims to define the state of art of SC therapy for PFDs in clinical trials, by systematically reviewing the available evidence. A systematic search strategy was conducted up to November 7, 2020, in PubMed, Scopus, Cochrane Library, and ISI Web of Science. Preclinical studies on animal models were not considered. Studies were included when the patients were affected by any PFDs and cells were isolated, cultured, and characterized as SC. The study protocol was registered in PROSPERO (CRD42020216551). A total of 11 prospective clinical studies were included in the final assessment, specifically 7 single-arm studies dealing with SC therapy for stress urinary incontinence and 4 with anal incontinence. Among the latter, there were two prospective, single-arm studies and two randomized controlled trials. No papers concerning the use of SC for prolapse repair were retrieved. Due to the great heterogeneity, data pooling was not possible. Stem cell injection resulted in a safe procedure, with few mild adverse side effects, mostly related to harvesting sites. However, a clear beneficial impact of SC treatment for the treatment of pelvic floor disorders could not be demonstrated. Further larger targeted studies with control arms are needed before any conclusions can be made.
盆腔器官脱垂(PFD)包括一系列可能难以忍受的疾病,会对生活质量产生负面影响。目前的治疗选择效果并不理想,因此需要新的治疗方法。干细胞(SC)疗法可能是一种替代治疗策略。本系统评价旨在通过系统回顾现有证据,确定临床试验中 SC 疗法治疗 PFD 的最新技术状态。截至 2020 年 11 月 7 日,我们在 PubMed、Scopus、Cochrane 图书馆和 ISI Web of Science 上进行了系统检索策略。未考虑针对动物模型的临床前研究。当患者患有任何 PFD 并且分离、培养和鉴定为 SC 时,研究才被纳入。研究方案已在 PROSPERO(CRD42020216551)中注册。最终评估共纳入 11 项前瞻性临床研究,具体涉及 7 项针对压力性尿失禁的 SC 治疗的单臂研究和 4 项针对肛门失禁的研究。后者中包括两项前瞻性单臂研究和两项随机对照试验。没有检索到关于使用 SC 治疗脱垂修复的论文。由于存在很大的异质性,无法进行数据合并。干细胞注射是一种安全的程序,只有少数轻微的不良反应,主要与采集部位有关。然而,不能证明 SC 治疗对治疗盆底功能障碍有明显的益处。在得出任何结论之前,需要进行更多有对照臂的大型靶向研究。